Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Innate immune system-directed vaccines

A vaccine, immune stimulation technology, applied in allergic diseases, peptides containing affinity tags, resistance to vector-borne diseases, etc., can solve problems such as differences in concepts, strategies and modes of action

Inactive Publication Date: 2004-11-24
YALE UNIV
View PDF9 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0028] Therefore, the aforementioned inventions are significantly different from the present invention in purpose, concept, strategy and mode of action

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Innate immune system-directed vaccines
  • Innate immune system-directed vaccines
  • Innate immune system-directed vaccines

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0240] The preparation of the injectable vaccine of the present invention involves mixing the chimeric construct with muramyl dipeptide or other carrier. The resulting mixture can be emulsified in a mannide monooleate / squalene or squalane vehicle. Four parts squalene and / or squalane are used per part mannide monooleate by volume. Methods of preparing vaccine compositions are well known to those of ordinary skill in the art. (Rola, Immunizing Agents and Diagnostic Skin Antigens. Described in Remington's Pharmaceutical Sciences, 18th Edition, Gennaro (ed.), (Mack Publishing Company 1990) pages 1389-1404).

[0241]Additional pharmaceutical carriers may be employed to control the duration of the vaccine in therapeutic applications. Controlled release formulations can be prepared by using polymers to complex or absorb the chimeric constructs. For example, biocompatible polymers include poly(ethylene-co-vinylacetate) matrices and matrices of polyanhydride copolymers of stearic ac...

Embodiment 1

[0266] Example 1. Model vaccine cassette with antigenic domain and PAMP domain

[0267] To produce a model vaccine cassette of the invention, we fused pathogen-associated molecular paradigms (PAMPs) to the characterized mouse antigen Eα. Our chosen PAMP, BLP, is known to stimulate the innate immune system through the receptor Toll-like receptor-2 (TLR-2).

[0268] The bacterial lipoprotein (BLP) protein sequence used in the vaccine cassette for fusion with the antigen of interest is as follows: MKATK LVLGA VILGS TLLAG CSSNA KIDQL SSDVQ TLNAK VDQLS NDVNAMRSDV QAAKD DAARA NQRLD NMATK YRK (SEQ ID NO: 2). The leader sequence includes amino acid 1 to amino acid 20 of SEQ ID NO:2. The first cysteine ​​(amino acid 21 of SEQ ID NO: 2) is lipidated in bacteria. This lipidation, which can only occur in bacteria, is essential for the recognition of BLP by Toll and TLRs. The C-terminal lysine (amino acid 78 of SEQ ID NO: 2) was mutated to increase the yield of the recombinant vaccine...

Embodiment 2

[0271] Example 2. Stimulation of NF-κB by BLP / Eα model antigen in RAW cells

[0272] To test whether model antigens can stimulate signal transduction pathways necessary for immune responses, we measured NF-κB activation in RAW mouse macrophage cell lines in vitro. We developed a stable RAW cell line containing the NF-κB-dependent firefly luciferase gene. Stimulation of these cells by activators of NF-κB results in the production of luciferase, which can be measured in cell lysates using a luminometer. Cells were stimulated with the indicated amounts of BLP / Eα for 5 hours and then harvested for luciferase measurements.

[0273] As a control, RAW cells were stimulated with LPS in the presence and absence of polymyxin B (PmB). PmB can inactivate endotoxin and, as expected, activation of NF-κB activity was reduced by 98% in LPS+PmB samples. BLP / Eα could also activate NF-κB in a dose-dependent manner as shown in Figure 4, however, treatment with PmB did not inactivate the stim...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides novel vaccines, methods for the production of such vaccines and methods of using such vaccines. The novel vaccines of the present invention combine both of the signals necessary to activate native T-cells-a specific antigen and the co-stimulatory signal-leading to a robust and specific T-cell immune response.

Description

field of invention [0001] The present invention relates to novel vaccines, their production and methods of using them. More specifically, the present invention provides unique vaccine molecules comprising an isolated Pathogen Associated Molecular Pattern (PAMP) and an antigen. More specifically, the present invention provides novel fusion proteins comprising an isolated PAMP and an antigen such that vaccination with these fusion proteins provides both signals required for natural T-cell activation. The novel vaccines of the present invention provide an efficient way to prepare and utilize a single molecule to induce a boosted T-cell immune response that activates other aspects of the adaptive immune response. The methods and compositions of the invention provide a powerful avenue for the design, production and use of vaccines targeting specific antigens, including those associated with selected pathogens, tumors, allergens and other disease-associated molecules. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/385A61P37/02
CPCC07K2319/02C07K2319/40C07K2319/21A61K2039/55561A61K2039/6068A61K39/385A61K2039/6025A61P37/02Y02A50/30
Inventor R·M·迈德齐托夫
Owner YALE UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com